INT6651

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 1991
Last Reported 2009
Negated 1
Speculated 0
Reported most in Abstract
Documents 18
Total Number 18
Disease Relevance 3.27
Pain Relevance 9.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (FPR1) signal transduction (FPR1) plasma membrane (FPR1)
signal transducer activity (FPR1)
Anatomy Link Frequency
neutrophils 4
PMNs 1
monocyte 1
renal pelvis 1
ureter 1
FPR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 406 100.00 Very High Very High Very High
agonist 93 100.00 Very High Very High Very High
substance P 24 100.00 Very High Very High Very High
Calcitonin gene-related peptide 8 100.00 Very High Very High Very High
bradykinin 32 99.90 Very High Very High Very High
Pain 171 98.84 Very High Very High Very High
antagonist 106 98.68 Very High Very High Very High
Morphine 6 98.52 Very High Very High Very High
analgesia 120 98.20 Very High Very High Very High
Enkephalin 245 98.08 Very High Very High Very High
Disease Link Frequency Relevance Heat
Urological Neuroanatomy 14 100.00 Very High Very High Very High
Pain 176 98.84 Very High Very High Very High
INFLAMMATION 275 97.48 Very High Very High Very High
Postoperative Complications 1 91.92 High High
Inflammatory Pain 114 86.32 High High
Injury 14 85.52 High High
Asthma 5 80.96 Quite High
Hypersensitivity 3 80.28 Quite High
Rhinitis 1 80.20 Quite High
Ganglion Cysts 1 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
HBSS 4.59 +/- 0.99%; P = 0.002), whereas neither nonactivated eosinophils nor cytochalasin B and FMLP in HBSS influenced SP release.
Localization (release) of FMLP in eosinophils associated with substance p
1) Confidence 0.73 Published 1997 Journal Am. J. Physiol. Section Abstract Doc Link 9374740 Disease Relevance 0.24 Pain Relevance 0.42
This was in contrast to results with aseanostatin P5 which selectively inhibited FMLP-induced MPO release.
Localization (release) of FMLP associated with urological neuroanatomy
2) Confidence 0.68 Published 1991 Journal J. Antibiot. Section Abstract Doc Link 1712007 Disease Relevance 0.49 Pain Relevance 0.45
In addition, these compounds inhibited the f-Met-Leu-Phe (FMLP)-induced MPO release from PMN.
Localization (release) of FMLP in PMN associated with urological neuroanatomy
3) Confidence 0.68 Published 1991 Journal J. Antibiot. Section Abstract Doc Link 1712007 Disease Relevance 0.44 Pain Relevance 0.49
Elastase releasing capacity was estimated by the fMLP-induced elastase release from separated neutrophils in vitro and expressed as % increase of released elastase activity induced by 0.2 microM fMLP.
Localization (release) of fMLP in neutrophils
4) Confidence 0.68 Published 1997 Journal Masui Section Abstract Doc Link 9028081 Disease Relevance 0.18 Pain Relevance 0.08
The histamine H1 antagonists mepyramine and ketotifen and the calcium antagonists verapamil, nifedipine and TMB-8 were also ineffective in suppressing FMLP-induced elastase release.
Localization (release) of FMLP associated with antagonist
5) Confidence 0.68 Published 1993 Journal Agents Actions Section Abstract Doc Link 8100381 Disease Relevance 0.54 Pain Relevance 0.44
In the present study we investigated the ability of N/OFQ, in comparison with the proinflammatory peptide formyl-Met-Leu-Phe (fMLP), to stimulate human neutrophil and monocyte chemotaxis and the release of lysozyme and superoxide anion (O2-) production from neutrophils. fMLP stimulated all the leukocyte functions examined.
Localization (release) of fMLP in monocyte
6) Confidence 0.57 Published 2005 Journal Peptides Section Abstract Doc Link 15922491 Disease Relevance 0 Pain Relevance 0.29
Both fMLP- and Mycobacterium butyricum-induced opioid peptide release was blocked by the specific FPR antagonists Boc-FLFLF (Fig. 4C, 6B) and cyclosporine H (Tables 1 and 2).
Localization (release) of fMLP associated with antagonist and opioid
7) Confidence 0.47 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2657213 Disease Relevance 0.18 Pain Relevance 0.43
Mycobacteria stimulate FPR-dependent intracellular calcium mobilization and PI3K-dependent release of opioid peptides
Localization (release) of FPR associated with opioid
8) Confidence 0.44 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2657213 Disease Relevance 0.05 Pain Relevance 0.61
Mycobacterium butyricum triggered intracellular Ca2+ mobilization in FPR -, but not in mock-transfected human embryonic kidney (HEK) 293 cells (Fig. 5A, B).
Localization (mobilization) of FPR in embryonic kidney
9) Confidence 0.44 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2657213 Disease Relevance 0 Pain Relevance 0.62
Finally, we tested the in vivo functional relevance of FPR agonist- and of Mycobacterium butyricum-induced opioid peptide release as an endogenous pathway of pain control in complete Freund's adjuvant-induced inflammation.
Localization (release) of FPR associated with pain, inflammation, agonist and opioid
10) Confidence 0.44 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2657213 Disease Relevance 0.40 Pain Relevance 0.84
We found that Mycobacterium butyricum induced opioid peptide release from neutrophils through FPR but not TLR stimulation.
Neg (not) Localization (release) of FPR in neutrophils associated with opioid
11) Confidence 0.44 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2657213 Disease Relevance 0.57 Pain Relevance 0.99
Previous studies delineated signaling requirements for fMLP-triggered release [24].
Localization (release) of fMLP
12) Confidence 0.41 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2657213 Disease Relevance 0.10 Pain Relevance 0.45
PMNs challenged with 10-7M FMLP released O2-.(2.1 ± 0.3 nmol citochrome C reduced/106 cells/min; n = 5).
Localization (released) of FMLP
13) Confidence 0.19 Published 2006 Journal J Inflamm (Lond) Section Body Doc Link PMC1435878 Disease Relevance 0.09 Pain Relevance 0.04
In the present study we investigated the ability of N/OFQ, in comparison with the proinflammatory peptide formyl-Met-Leu-Phe (fMLP), to stimulate human neutrophil and monocyte chemotaxis and the release of lysozyme and superoxide anion (O2-) production from neutrophils. fMLP stimulated all the leukocyte functions examined.
Localization (release) of fMLP in neutrophil
14) Confidence 0.19 Published 2005 Journal Peptides Section Abstract Doc Link 15922491 Disease Relevance 0 Pain Relevance 0.29
Both bradykinin and FMLP evoked the release of CGRP-like immunoreactivity in the renal pelvis.
Localization (release) of FMLP in renal pelvis associated with bradykinin and calcitonin gene-related peptide
15) Confidence 0.19 Published 1992 Journal J. Urol. Section Abstract Doc Link 1331550 Disease Relevance 0 Pain Relevance 1.07
By contrast neither bradykinin nor FMLP did evoke a significant CGRP-LI release in the ureter.
Localization (release) of FMLP in ureter associated with bradykinin and calcitonin gene-related peptide
16) Confidence 0.19 Published 1992 Journal J. Urol. Section Abstract Doc Link 1331550 Disease Relevance 0 Pain Relevance 1.10
7M) and negative controls (absence of fMLP).
Localization (absence) of fMLP
17) Confidence 0.13 Published 2009 Journal Molecular Human Reproduction Section Body Doc Link PMC2762373 Disease Relevance 0 Pain Relevance 0
Morphine was found to inhibit PMNs aggregation induced by PHA (0.01), PMA (0.01), fMLP (0.01) and Ca++ ionophore (p < 0.01), ATP release (p < 0.01), thromboxane B2 (TxB2) and leukotriene B4 (LTB4) secretion during cell aggregation.
Localization (secretion) of fMLP in PMNs associated with morphine
18) Confidence 0.08 Published 1993 Journal Riv Eur Sci Med Farmacol Section Abstract Doc Link 7909619 Disease Relevance 0 Pain Relevance 1.28

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox